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Summary
Background: Data regarding incidence, prevalence and long-term outcomes of in-
flammatory bowel diseases in the UK are limited or outdated.
Aims: To investigate incidence and prevalence of Crohn's disease and ulcerative coli-
tis and risk of colorectal cancer and all-cause mortality in these diseases.
Methods: Inflammatory bowel disease cases between 2000 and 2018 were identi-
fied from a national primary care database. Inflammatory bowel disease prevalence 
was forecast until 2025. The association between inflammatory bowel disease and 
colorectal cancer and all-cause mortality was investigated using age/sex-matched 
retrospective cohort studies. Hazard ratios were adjusted for age, sex, deprivation, 
comorbidity, smoking status and body mass index.
Results: Ulcerative colitis prevalence increased from 390 to 570 per 100 000 popula-
tion from 2000 to 2017. Prevalence of Crohn's disease increased from 220 to 400 per 
100 000. In 2017 male Crohn's disease prevalence was 0.35% (95% confidence in-
terval 0.34-0.36); female prevalence was 0.44% (0.43-0.45). Prevalence of inflamma-
tory bowel disease is predicted to be 1.1% by 2025. Incidence of ulcerative colitis and 
Crohn's disease was 23.2 (22.8-23.6) and 14.3 (14.0-14.7) per 100 000 person-years 
respectively. Subjects with ulcerative colitis were more likely to develop colorec-
tal cancer than controls (adjusted Hazard Ratio 1.40 [1.23-1.59]). Colorectal cancer 
rates remained stable in inflammatory bowel diseases over time. Ulcerative colitis 
and Crohn's disease were associated with increased risk of all-cause mortality (1.17 
[1.14-1.21] and 1.42 [1.36-1.48] respectively).
Conclusions: The UK prevalence of inflammatory bowel disease is greater than previ-
ous reports suggest and we predict an 11% increase in prevalence by the year 2025. 
Mortality risk in inflammatory bowel disease and colorectal cancer risk in ulcerative 
colitis are increased compared to matched controls.
     |  923KING et al.
1  | INTRODUC TION
Inflammatory bowel diseases are characterised by chronic and re-
lapsing inflammation of the bowel. They can affect any age group, 
have a significant impact on working age populations and lead to a 
considerable societal and economic burden.1,2 Inflammatory bowel 
disease largely consists of two sub-phenotypes: Crohn's disease and 
ulcerative colitis. The global epidemiology of inflammatory bowel 
disease has changed substantially over time, with a recent review 
demonstrating an increasing incidence of inflammatory bowel dis-
ease in developing nations and a stabilising incidence in developed 
nations.3,4 Similarly, all-cause mortality rates within the inflamma-
tory bowel disease cohort have improved significantly, with recent 
research suggesting rates similar to those of the general population.5 
Historically a key risk factor for mortality in the inflammatory bowel 
disease cohort was thought to be the association between inflam-
matory bowel disease and colorectal cancer (CRC)6; however, recent 
evidence suggests that this risk is now much lower than previously 
thought.7,8
Inflammatory bowel disease can lead to hospitalisation and 
time off work, and its management is costly. Given the individual 
and societal impact of these diseases, accurate and up-to-date data 
on prevalence and outcomes are important for service planning. 
Published United Kingdom (UK) inflammatory bowel disease epi-
demiology data are out of date or based on small or regional data-
sets which may not be representative of the United Kingdom as a 
whole.4,9-12
The primary aim of this study was to provide an up-to-date de-
scription of the incidence and prevalence of inflammatory bowel 
diseases in the UK and forecast the expected prevalence of these 
conditions. The secondary aim was to quantify the risk of all-cause 
mortality and colorectal cancer (CRC) in the inflammatory bowel dis-
ease cohort.
2  | MATERIAL S AND METHODS
2.1 | Data source
This study utilised The Health Improvement Network primary 
care (THIN) database. This is derived from 787 general practices 
across the UK and incorporates data from approximately 15 mil-
lion subjects. It is generalisable to the UK population.13 Longitudinal 
patient-level data including medication use, primary and secondary 
care investigations and diagnoses are uploaded electronically using 
a hierarchy of clinical (Read) codes.14 Diagnoses of inflammatory 
bowel disease are derived from general practitioners who receive 
this data from secondary and tertiary centres where the diagnosis 
would have been established. Practices were included in the study 
if they had achieved an acceptable mortality recording threshold 
and at least one year had elapsed since the installation of the elec-
tronic medical record system.15 Inclusion only after attainment of an 
acceptable level of data recording (assessed by acceptable mortality 
recording) reduces the risk of under-recording.
2.2 | Study design
Cross-sectional and retrospective cohort studies were carried out 
to identify the annual point prevalence and incidence rates, respec-
tively, of ulcerative colitis and Crohn's disease among adults aged 
18 years and over between 1 January 2000 and 31 December 2017. 
Incident cases were defined as new cases during the study period 
without a previous diagnosis before entry date. Prevalent cases 
were defined as cases diagnosed/recorded before the annual point 
prevalence calculation for the year of interest.
The prevalence of ulcerative colitis and Crohn's disease was 
projected forward to 2025 using Holt-Winters’ double exponen-
tial smoothing model with 80 and 95% prediction intervals (PI). For 
the model validation, the dataset was separated into two portions: 
training (from 2000 to 2012) and test (from 2013 to 2017) data. The 
model was fitted to the training data and predicted prevalence up to 
2017 compared with test data.
The incidence of colorectal cancer was determined in the whole 
adult, THIN database population and in those with ulcerative colitis 
and Crohn's disease. Mortality and colorectal cancer incidence rates 
were quantified using matched cohort studies between 1 January 
2000 and the date of the latest data available at the time of study (17 
January 2018). Four controls, unexposed to either ulcerative colitis 
or Crohn's disease, were directly matched for each ulcerative colitis 
or Crohn's disease subject by age, sex, Townsend deprivation level16 
and index date. Index date was defined as the date of diagnosis of 
ulcerative colitis or Crohn's disease for incident cases and one year 
after joining an eligible practice for prevalent cases. If individuals 
in the colorectal cancer study had a previous record of colorectal 
cancer prior to the study start date, they were excluded. Subjects 
with a colectomy code prior to cancer diagnosis were excluded from 
the colorectal cancer study. Subjects were followed up until the out-
come of interest, death or the earlier of a subject leaving the practice 
or the final collection of data on a subject. If subjects were coded 
for both ulcerative colitis and Crohn's disease, the later of the two 
was considered the diagnosis while the earliest diagnosis date was 
retained.
2.3 | Data validation
Clinical codes used to identify ulcerative colitis, Crohn's disease and 
colorectal cancer are listed in Appendix S1. Code lists used to identify 
patients with inflammatory bowel disease have been previously vali-
dated.17,18 For internal validity, 88 practices were examined during the 
study time period. Subjects coded with ulcerative colitis were assessed 
to ascertain whether they had ever had medical treatment (thiopurine 
[azathioprine or mercaptopurine] or mesalazine) or definitive surgical 
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treatment in the form of colectomy or both. This methodology was 
replicated in subjects with Crohn's disease; however, all bowel resec-
tion surgeries and perianal surgical procedures were also included.
2.4 | Statistical analysis
2.4.1 | Incidence and prevalence
Annual point prevalence of ulcerative colitis and Crohn's disease 
was calculated on 31 December each year per 100 000 popula-
tion and was stratified by sex. Point prevalence for ulcerative coli-
tis and Crohn's disease in 2000 and 2017 was standardised to an 
adult UK age-sex standardised population for these years derived 
from the Office for National Statistics data (ONS).19 Incidence rates 
per 100 000 person-years (py) were calculated from 1 January to 31 
December annually. Incidence was stratified by sex and 10-year age 
bands over the study period and annually. Multivariable Poisson re-
gression models were used to calculate incidence rate ratios (IRR) for 
ulcerative colitis and Crohn's disease, adjusting for age band, sex and 
year of study.
2.4.2 | Mortality and colorectal cancer outcomes
Baseline characteristics were compared using Chi-squared tests for 
categorical variables and Student t-tests for continuous variables. A 
multivariable Cox proportional hazards model was used to quantify 
colorectal cancer risk, adjusting for sex, body mass index (BMI) at 
index date, Townsend deprivation quintile, Charlson comorbidity score 
and smoking status. A further multivariable Cox proportional hazard 
model was used to derive adjusted hazard ratios (aHR) to quantify risk 
of mortality, adjusting for the same variables.16,20 The proportional 
hazards assumption was tested using log-log plots. Missing values 
were included as separate categories. Kaplan-Meier survival analyses 
for all-cause mortality were performed in ulcerative colitis and Crohn's 
disease subjects and their controls. Poisson regression models adjust-
ing for year, age at index date and sex were used to assess trends in 
colorectal cancer in ulcerative colitis and Crohn's disease. Standardised 
mortality ratios (SMR) annually and overall were produced for both ul-
cerative colitis and Crohn's disease using UK standardised mortality 
rates for each year of the study, derived from the Office for National 
Statistics data.21 Analyses were performed using Stata version 15.022 
and P < 0.05 were considered statistically significant.
2.5 | Sensitivity analysis
The impact of age on the risk of mortality and colorectal cancer 
was assessed through sensitivity analysis excluding subjects over 
70 years old at index date. This analysis may improve internal 
validity due to the reduced proportion with inflammatory bowel 
disease drugs or inflammatory bowel disease surgery observed 
in older age bands. The colorectal cancer and mortality studies 
were performed with a combination of incident and prevalent 
cases. A sensitivity analysis including only incident cases of ul-
cerative colitis or Crohn's disease and their respective controls 
was undertaken.
3  | RESULTS
3.1 | Validation
Within the validation cohort there were 2578 subjects with ul-
cerative colitis (median age 47 [IQR 33-62] years, 49.6% female). 
Eighty-nine percent of subjects with a diagnostic code for ulcerative 
colitis had a record of either an inflammatory bowel disease drug 
or a colectomy. The Crohn's disease validation cohort consisted of 
1943 subjects (median age 41 [IQR 27-56] years, 56.3% female). 
Eighty-seven percent of Crohn's disease subjects had a code with 
an inflammatory bowel disease drug or an appropriate surgery re-
corded. When ulcerative colitis or Crohn's disease and an inflamma-
tory bowel disease drug, excluding surgical codes, were examined, 
co-coding was observed in 87.6% and 81.0% of cases respectively 
(Appendix S2).
3.2 | Cohort for prevalence and incidence studies
Seven hundred and eighty-seven general practices are included in 
The Health Improvement Network database. The 787 practices con-
tributed 8 486 415 subjects to the study based on the study period, 
population age and data quality requirements as previously de-
scribed. 71.6% of subjects came from English primary care practices, 
3.6% from Northern Irish practices, 14% from Scottish practices and 
10.8% from Welsh practices.
3.3 | Prevalence of ulcerative colitis and 
Crohn's disease
The annual point prevalence of ulcerative colitis over the study pe-
riod increased from 390 per 100 000 population in 2000 to 570 per 
100 000 in 2017 (Figure 1), with an average increase of 2.5% per 
annum. Prevalence of ulcerative colitis was similar among males and 
females. In 2000, age-sex standardised point prevalence of ulcerative 
colitis was 365 per 100 000 population for adult males, 372 for adult 
females and 369 per 100 000 overall. In 2017 the standardised rates 
were 662 for males, 615 for females and 637 per 100 000 popula-
tion overall. The prevalence of Crohn's disease increased from 220 to 
400 per 100 000 over the 18 years studied, an average rise of 3.5% 
per annum. When stratified by sex, there were more female subjects 
with Crohn's disease (Figure 1). The standardised point prevalence of 
Crohn's disease was 189 for males, 235 for females and 213 per 100 
000 population overall. In 2017, Crohn's disease point prevalence for 
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males was 354 and for females 448 per 100 000, with an overall adult 
prevalence of 403 per 100 000 population in 2017.
Using Holt-Winters’ double exponential smoothing model, ulcer-
ative colitis and Crohn's disease prevalence were forecast forward 
to the year 2025. Ulcerative colitis prevalence in 2025 was forecast 
to be 592.6 (95% PI 490.3-694.9) per 100 000 and Crohn's disease 
prevalence was forecast to be 487.2 (95% PI 470.7-503.8) per 100 
000. Time series graphs with actual and forecasted prevalence of 
ulcerative colitis and Crohn's disease are shown in Appendix S3.
3.4 | Incidence of ulcerative colitis and 
Crohn's disease
Between 2000 and 2018, in the study of incidence, 12 787 incident 
cases of ulcerative colitis were identified, with an overall incidence 
rate of 23.2 (95% CI 22.8-23.6) per 100 000 person-years (py). A bi-
modal profile of incidence rates by age was identified, with peaks in 
the 30-40 and 60-80 age groups (Appendix S4). Incidence was higher 
in males compared to females (24.4 [23.9-25.0] and 22.1 [21.5-22.6] 
per 100 000 person-years respectively). Adjusting for year and sex, 
females had a 10% lower risk of developing ulcerative colitis compared 
to males between 2000 and 2018 (incidence rate ratio 0.90 [0.87-
0.93], P < 0.001). The overall incidence of ulcerative colitis fell during 
the study period from 25 per 100 000 person-years in 2000 to 20 
per 100 000 person-years in 2017, an average of 1.6% per annum, 
incidence rate ratio 0.98 (95% CI 0.98-0.99), P < 0.001. Incidence re-
mained stable in those aged under 50 years of age (incidence rate ratio 
1.02 [95% CI 1.01-1.02], P < 0.001) but fell in those aged 50 and over 
(incidence rate ratio 0.93 [0.93-0.94], P < 0.001). Trends in incidence 
rates overall and among males and females are shown in Figure 2. 7904 
incident cases of Crohn's disease were identified in the study of inci-
dence, with an overall incidence rate of 14.3 (14.0-14.7) per 100 000 
py. A bimodal incidence rate age profile was again demonstrated, with 
a higher peak in the 18-30-year age category and a smaller peak in the 
60-70 age group (Appendix S4). Crohn's disease incidence rates were 
stable over the study period with a higher incidence of Crohn's disease 
in females compared to males (12.8 [12.4-13.2] and 15.8 [15.4-16.3] 
respectively) (Figure 2). Adjusting for year, females had a 23% higher 
incidence of Crohn's disease compared to males (incidence rate ratio 
1.23 [1.18-1.29], P < 0.001). The overall incidence of Crohn's disease, 
adjusting for year of study, remained stable over the study period (in-
cidence rate ratio 0.99 [0.99-1.00], P = 0.590). In those aged under 
50 years, the incidence increased slightly over time (incidence rate 
F I G U R E  1   Annual point prevalence of 
ulcerative colitis and Crohn's disease per 
100 000 population. CD, Crohn's disease; 
UC, ulcerative colitis
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F I G U R E  2   Annual incidence rate of 
ulcerative colitis and Crohn's disease 
per 100 000 person-years. CD, Crohn's 
disease; UC, ulcerative colitis
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ratio 1.03 [1.03-1.04], P < 0.001), but in those aged 50 and over, the 
incidence fell by 5% (incidence rate ratio 0.95 [0.94-0.96], P < 0.001).
3.5 | Colorectal cancer risk in ulcerative colitis and 
Crohn's disease
The colorectal cancer (CRC) incidence rate for the whole adult THIN 
population was 64.6 (95% CI 63.9-65.3) per 100 000 py over the 
study period. The rate in females was 57.3 (56.4-58.2) and in males 
72.1 (71.1-73.1) per 100 000 py.
In the matched ulcerative colitis colorectal cancer cohort study, 
37 793 subjects with ulcerative colitis (12 319 (33%) incident cases 
and 25 474 (67%) prevalent cases) were matched to 148 126 con-
trol subjects contributing 242 407 and 966 522 person-years at risk 
respectively. Baseline demographic characteristics are shown in 
Table 1 and a comparison of incident and prevalent case demograph-
ics is shown in Appendix S5. Three hundred and twenty-eight (0.87%) 
new cases of colorectal cancer were observed in the ulcerative coli-
tis group and 917 (0.62%) new cases in the control group. The in-
cidence rate of colorectal cancer in ulcerative colitis subjects was 
135.3 (121.2-150.9) per 100 000 py compared to 94.9 (85.9-97.7) in 
 
Ulcerative colitis 
(%)
Ulcerative colitis 
controls (%)
Crohn's disease 
(%)
Crohn's disease 
controls (%)
N 37 793 (20.33) 148 126 (79.67) 26 160 (20.27) 102 881 (79.73)
Male 18 860 (49.90) 73 840 (49.86) 11 534 (44.09) 45 327 (44.06)
Female 18 933 (50.10) 74 286 (50.14) 14 626 (56.91) 57 554 (55.94)
Age, median (IQR) 51 (37-65) 50 (37-64) 43 (31-58) 43 (31-58)
Age, n (%)
18-30 4723 (12.50) 18 609 (12.56) 5817 (22.24) 22 887 (22.25)
30-40 6519 (17.25) 25 866 (17.46) 5532 (21.15) 22 095 (21.48)
40-50 6793 (17.97) 27 045 (18.26) 4777 (18.26) 18 968 (18.44)
50-60 6896 (18.25) 27 326 (18.45) 3922 (14.99) 15 497 (15.06)
60-70 6088 (16.11) 23 685 (15.99) 3087 (11.80) 12 059 (11.72)
70-80 4328 (11.45) 16 746 (11.31) 1999 (7.64) 7699 (7.48)
>80 2446 (6.47) 8849 (5.97) 1026 (3.92) 3676 (3.57)
Deprivation score
1 (least deprived) 8672 (22.95) 34 175 (23.07) 5367 (20.52) 21 201 (20.61)
2 7613 (20.14) 29 940 (20.21) 4915 (18.79) 19 400 (18.86)
3 7077 (18.73) 27 841 (18.8) 4915 (18.79) 19 402 (18.86)
4 5592 (14.80) 21 948 (14.82) 4180 (15.98) 16 386 (15.93)
5 (most deprived) 3353 (8.87) 12 894 (8.70) 2970 (11.35) 11 470 (11.15)
Missing 5486 (14.52) 21 328 (14.40) 3813 (14.58) 15 022 (14.60)
Charlson comorbidity score
0 24 469 (64.74) 103 970 (70.19) 17 344 (66.30) 75 238 (73.13)
1 8134 (21.52) 28 044 (18.93) 6085 (23.26) 19 187 (18.65)
2 2889 (7.64) 8939 (6.03) 1568 (5.99) 4859 (4.72)
3 1282 (3.39) 4185 (2.83) 693 (2.65) 2128 (2.07)
4+ 1019 (2.70) 2988 (2.02) 470 (1.80) 1469 (1.43)
Smoking status
Smoker 4660 (12.33) 29 648 (20.02) 6795 (25.97) 22 259 (21.64)
Nonsmoker 20 492 (54.22) 76 393 (51.57) 12 078 (46.17) 52 991 (51.51)
Ex-smoker 9964 (26.36) 27 056 (18.27) 5417 (20.71) 16 651 (16.18)
Missing 2677 (7.08) 15 029 (10.15) 1870 (7.15) 10 980 (10.67)
Body mass index
<25 kg/m2 14 547 (38.49) 50 565 (34.14) 11 422 (43.66) 36 315 (35.3)
25-30 kg/m2 10 660 (28.21) 39 871 (26.92) 6105 (23.34) 24 640 (23.95)
>30 kg/m2 5497 (14.55) 23 857 (16.11) 3391 (12.96) 16 095 (15.62)
Missing 7089 (18.76) 33 833 (22.84) 5242 (20.04) 25 831 (25.11)
TA B L E  1   Colorectal cancer study: 
cohort demographics
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the control group, giving an unadjusted incidence rate ratio of 1.43 
(1.25-1.62), P < 0.001. After adjusting for age, year, sex, deprivation 
quintile, comorbidity, body mass index and smoking status, aHR was 
1.40 (1.23-1.59), P < 0.001 (Table 2). In a sensitivity analysis, exclud-
ing subjects aged > 70, aHR was 1.56 (1.33-1.83), P < 0.001. The 
absolute risk of colorectal cancer in ulcerative colitis subjects was 
0.87%. In the incident only analysis, 54 cases of colorectal cancer 
were observed among 12 319 incident cases contributing 67 334 
person-years at risk, compared to the control group where 222 cases 
were observed in 48 514 control subjects contributing 264 791 per-
son-years at risk. This is lower than was seen in the prevalent and 
incident data with a crude incidence rate ratio of 0.97 (0.70-1.29), 
P = 0.390 and an adjusted Hazard ratio of 0.91 (0.68-1.23), P = 0.553 
(incident only data presented in Appendix S8).
In the Crohn's disease colorectal cancer matched cohort study, 
26 160 subjects with Crohn's disease (8115 [31%] incident cases and 
TA B L E  2   Multivariable Cox proportional hazard model of factors associated with colorectal cancer
 
Ulcerative colitis
 
Crohn's disease
Hazard ratio
[95% Conf. 
interval] P Hazard Ratio
[95% Conf. 
Interval] P
Ulcerative colitis 1.40 1.23 1.59 <0.001 Crohn's disease 1.19 0.97 1.46 0.096
Age band
Reference 18-30 1.00     1.00    
30-40 1.45 0.73 2.89 0.290  4.06 1.55 10.61 0.004
40-50 3.64 1.95 6.79 <0.001  9.30 3.72 23.24 <0.001
50-60 7.97 4.34 14.60 <0.001  23.07 9.40 56.61 <0.001
60-70 15.11 8.27 27.60 <0.001  40.53 16.57 99.16 <0.001
70-80 22.57 12.34 41.28 <0.001  65.65 26.75 161.10 <0.001
>80 25.22 13.56 46.90 <0.001  76.55 30.30 193.39 <0.001
Sex
Reference Male 1.00     1.00    
Female 0.75 0.67 0.84 <0.001  0.77 0.65 0.92 0.003
Smoking status
Reference 
Nonsmoker
1.00     1.00    
Smoker 0.96 0.81 1.14 0.618  0.83 0.65 1.07 0.159
Ex-smoker 1.03 0.89 1.18 0.727  1.05 0.85 1.31 0.644
Missing 1.03 0.83 1.29 0.782  1.00 0.73 1.37 0.986
Body mass index kg/m2
Reference <25 1.00     1.00    
25-30 1.02 0.88 1.17 0.804  1.04 0.83 1.29 0.741
>30 1.08 0.91 1.28 0.362  1.03 0.79 1.34 0.835
Missing 0.95 0.79 1.15 0.608  1.21 0.93 1.59 0.161
Charlson Score
Reference 0 1.00     1.00    
1 1.10 0.96 1.27 0.176  0.99 0.80 1.23 0.954
2 1.21 1.01 1.46 0.044  1.02 0.76 1.38 0.883
3 1.39 1.08 1.78 0.011  0.65 0.38 1.11 0.114
4+ 1.47 1.09 2.00 0.012  1.27 0.78 2.07 0.333
Deprivation score
Reference 1 1.00     1.00    
2 1.06 0.90 1.24 0.500  1.09 0.84 1.42 0.508
3 1.03 0.87 1.22 0.715  1.15 0.89 1.50 0.285
4 1.03 0.85 1.24 0.774  1.16 0.87 1.53 0.308
5 (most deprived) 1.11 0.89 1.39 0.346  1.14 0.83 1.57 0.422
Missing 0.89 0.73 1.10 0.281  1.01 0.74 1.38 0.954
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18 045 [69%] prevalent cases) were matched to 102 881 control sub-
jects contributing a total of 158 906 and 647 624 person-years at 
risk respectively. Baseline demographic characteristics are shown in 
Table 1 and a comparison of incident and prevalent case demograph-
ics is shown in Appendix S5. One hundred and twenty (0.46%) cases 
of colorectal cancer were observed in the Crohn's disease group and 
423 (0.41%) in the control group. The incidence rate of colorectal 
cancer in Crohn's disease subjects was 75.5 per 100 000 py (62.6-
90.3) compared to 65.3 (59.2-71.8) in the control group, giving an un-
adjusted incidence rate ratio of 1.16 (0.93-1.42), P = 0.082. Following 
adjustment for covariates, aHR was 1.19 (0.97-1.46), P = 0.096. The 
absolute risk of colorectal cancer in Crohn's disease cases was 
0.46%. Increased risk of colorectal cancer in younger subjects with 
Crohn's disease was seen in a sensitivity analysis, excluding subjects 
aged over 70 years old: aHR 1.29 (1.01-1.65), P = 0.043. Adjusting 
for age and sex, both the Crohn's disease colorectal cancer rate (inci-
dence rate ratio 0.99 (0.96-1.04), P = 0.960) and the ulcerative colitis 
colorectal cancer rate (1.02 (0.99-1.04), P = 0.158), were stable over 
time. Trends in colorectal cancer rates among the ulcerative colitis 
and Crohn's disease cohorts are graphically represented in Figure 3. 
In the incident only analysis, 39 cases of colorectal cancer were 
observed among 8115 incident Crohn's disease cases accounting 
for 42 627 person-years at risk. This compared to 117 cases in the 
unexposed group of 31 946 control subjects which accounted for 
169 221 person-years at risk. This gives a crude incidence rate ratio 
of 1.32 (0.90-1.92), P = 0.068. An adjusted hazard ratio for incident 
Crohn's disease cases was 1.34 (0.93-1.93), P = 0.118 (incident only 
data are presented in Appendix S8).
3.6 | Mortality in ulcerative colitis and 
Crohn's disease
In the matched ulcerative colitis cohort study addressing mortality 
risk, 42 179 subjects with ulcerative colitis were matched to 166 083 
control subjects contributing 276 312 and 1 099 868 person-years 
at risk respectively. During the study period 4807 (11.4%) ulcera-
tive colitis subjects and 16 098 (9.7%) matched controls died. The 
absolute risk difference between ulcerative colitis and control sub-
jects was 1.7%. Cohort characteristics are shown in Appendix S6. 
Ulcerative colitis subjects were more likely to die than matched con-
trols: aHR 1.17 (95% CI 1.14-1.21), P < 0.001 (Table 3 and Appendix 
S7). In sensitivity analysis, excluding subjects age >70, aHR was 1.13 
(1.07-1.20), P < 0.001. The factors associated with death in subjects 
with ulcerative colitis when assessed separately were age above 18-
30, P < 0.001, current and ex-smoking (1.58 [1.43-1.74], P < 0.001 
and 1.09 [1.02-1.16], P = 0.017 respectively), deprivation levels 
greater than level 2 and additional comorbidities. The factors associ-
ated with a reduced risk of mortality among subjects with ulcerative 
colitis were female sex (0.77 [0.73-0.82], P < 0.001) and body mass 
index in the range of 25-30 kg/m2 when compared to those <25 kg/
m2 (0.86 [0.80-0.93], P < 0.001). When adjusting for age and sex, 
ulcerative colitis mortality remained unchanged over the duration 
of the study period with an incidence rate ratio of 0.99 (0.99-1.00), 
P = 0.309. The standardised mortality ratio for ulcerative colitis sub-
jects was 0.96 (0.93-0.99) and annual standardised mortality ratios 
for ulcerative colitis are presented in Figure 4. In the incident only 
analysis, 1134 deaths were observed among 13 122 ulcerative coli-
tis subjects accounting for 73 069 person-years at risk compared to 
3533 deaths among 51 927 control subjects contributing 287 404 
person-years at risk. This provides a crude incidence rate ratio of 
1.26 (1.18-1.35), P < 0.001, an adjusted HR of 1.31 (1.23-1.41), 
P < 0.001 and an absolute risk difference of 1.84% (incident only 
data presented in Appendix S8).
In the Crohn's disease matched cohort study addressing mortality 
risk, 27 870 subjects with Crohn's disease were matched to 110 005 
control subjects contributing 171 906 and 700 975 person-years at 
risk respectively. During the study period, 2612 (9.4%) Crohn's dis-
ease subjects and 7137 (6.5%) matched control subjects died. The 
absolute risk difference between Crohn's disease and control sub-
jects was 2.88%. Crohn's disease subjects were more likely to die 
than matched controls: aHR 1.42 (1.36-1.48), P < 0.001 (Table 3 and 
Appendix S7). This risk increased when those > 70 were excluded 
in the sensitivity analysis to 1.49 (1.40-1.60), P < 0.001. The factors 
associated with mortality in Crohn's disease when assessed sepa-
rately were age greater than 18-30, current and ex-smoking (1.87 
F I G U R E  3   Colorectal cancer rates 
in ulcerative colitis and Crohn's disease 
subjects over the study period
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[1.69-2.07], P < 0.001 and 1.17 [1.06-1.29], P < 0.001 respectively), 
deprivation and additional comorbidities. As with ulcerative colitis, 
the factors associated with a reduced risk of mortality in subjects 
with Crohn's disease were female sex (0.87 [0.81-0.95], P < 0.001) 
and body mass index in the range of 25-30 kg/m2 when compared 
to those <25 kg/m2 (0.88 [0.78-0.99], P = 0.045). Over the study 
period, adjusting for age and sex, Crohn's disease mortality fell 
slightly; incidence rate ratio was 0.99 (0.98-0.99), P = 0.009. Over 
the study period the standardised mortality ratio (SMR) for Crohn's 
disease subjects was 1.26 (1.21-1.30), annual standardised mortality 
ratios for Crohn's disease are presented in Figure 4. In the incident 
only analysis, 689 deaths were observed among 8442 Crohn's dis-
ease subjects, contributing 44 856 person-years at risk, compared 
to 1711 deaths observed in 33 371 control subjects contributing 
178 235 person-years at risk. This gives a crude incidence rate ratio 
of 1.60 (1.46-1.75), P < 0.001, an absolute risk difference of 3.0% 
and an adjusted HR of 1.50 (1.37-1.64), P < 0.001 (incident only data 
presented in Appendix S8).
TA B L E  3   Multivariable Cox proportional hazard model of factors associated with all-cause mortality
Ulcerative colitis
Ulcerative colitis  Crohn's disease
Hazard ratio [95% Conf. interval] P  Hazard ratio [95% Conf. interval] P
1.17 1.14 1.21 <0.001 Crohn's disease 1.42 1.36 1.48 <0.001
Age band
Reference 18-30 1.00     1.00    
30-40 2.21 1.69 2.88 <0.001  2.78 2.11 3.65 <0.001
40-50 4.78 3.72 6.14 <0.001  6.20 4.80 8.02 <0.001
50-60 11.76 9.22 15.01 <0.001  16.22 12.65 20.79 <0.001
60-70 29.34 23.04 37.36 <0.001  37.29 29.17 47.68 <0.001
70-80 75.71 59.49 96.36 <0.001  95.99 75.13 122.64 <0.001
>80 196.94 154.68 250.76 <0.001  244.55 191.16 312.86 <0.001
Sex
Reference Male 1.00     1.00    
Female 0.79 0.77 0.81 <0.001  0.80 0.77 0.83 <0.001
Smoking status
Reference 
Nonsmoker
1.00     1.00    
Smoker 1.81 1.74 1.88 <0.001  1.95 1.85 2.06 <0.001
Ex-smoker 1.12 1.08 1.16 <0.001  1.22 1.16 1.28 <0.001
Missing 1.14 1.08 1.20 <0.001  1.28 1.19 1.39 <0.001
Body mass index kg/m2
Reference < 25 1.00     1.00    
25-30 0.85 0.82 0.88 <0.001  0.82 0.78 0.87 <0.001
>30 0.95 0.91 0.99 0.011  0.94 0.88 1.00 0.036
Missing 1.25 1.20 1.30 <0.001  1.21 1.14 1.29 <0.001
Charlson Score
Reference 0 1.00     1.00    
1 1.61 1.56 1.67 <0.001  1.69 1.60 1.78 <0.001
2 2.01 1.93 2.10 <0.001  2.20 2.07 2.33 <0.001
3 2.46 2.34 2.59 <0.001  2.63 2.44 2.83 <0.001
4+ 3.68 3.50 3.87 <0.001  3.82 3.54 4.13 <0.001
Deprivation score
Reference 1 1.00     1.00    
2 1.08 1.03 1.12 0.001  1.11 1.04 1.19 0.002
3 1.23 1.18 1.29 <0.001  1.18 1.11 1.26 <0.001
4 1.35 1.29 1.41 <0.001  1.32 1.24 1.41 <0.001
5 (most deprived) 1.43 1.36 1.51 <0.001  1.42 1.32 1.52 <0.001
Missing 1.17 1.11 1.23 <0.001  1.17 1.09 1.27 <0.001
930  |     KING et al.
4  | DISCUSSION
This study has examined in detail the UK epidemiology of ulcera-
tive colitis and Crohn's Disease using a large, population-based data-
set. Previous reports of the epidemiology of ulcerative colitis and 
Crohn's disease in the UK have used comparatively small datasets or 
focused on regional areas which may not be generalisable to the UK 
population as a whole or are now largely historic.9,11,12 As with other 
high-prevalence areas,3,4 this study shows that ulcerative colitis and 
Crohn's disease prevalence in the UK have been increasing over the 
past two decades at a rate of 2%-3% per annum. This is in keeping 
with a recent study from Canada which has forecast a 35% increase 
in those living with inflammatory bowel disease over the next dec-
ade.23 The UK population in mid-2017 was estimated at 66 million.24 
Applying the findings of this study, an unadjusted estimate of the 
number of people living with ulcerative colitis in the UK in 2017 
would be 376 000 and with Crohn's disease 264 000. This translates 
to an inflammatory bowel disease prevalence of 640 000 people or 
0.97% of the population. The UK population in 2025 is predicted to 
be 68.9 million.25 This study has forecast a combined inflammatory 
bowel disease prevalence of 1080 per 100 000 by 2025, equating to 
744 120 living with inflammatory bowel disease in the UK or 1.1% 
of the population. How novel therapeutics, surgery, an older popu-
lation and multidisciplinary management of these conditions might 
mitigate such an increase in prevalence is uncertain,26,27 but these 
findings are fundamental for future planning of services in inflam-
matory bowel disease. The increasing prevalence of inflammatory 
bowel disease likely represents a reduction in mortality over time, 
given the slight decrease observed in incidence rates for these dis-
eases. The cautious forecasting undertaken in this study represents 
a realisation that prevalence is likely to stabilise as, in due course, life 
expectancy plateaus.
The incidence of both ulcerative colitis and Crohn's disease is 
relatively stable, with an observed reduction in ulcerative colitis 
incidence rates over the study period. This is mainly driven by 
a more significant reduction in those over 50 years while little 
change was observed in those under 50 years old. Inflammatory 
bowel disease diagnosis in the elderly can be challenging due to a 
range of differential diagnoses and phenotypic differences when 
compared to younger groups.28 The internal validation work pre-
sented in this study has sought to examine miscoding bias among 
subjects with inflammatory bowel disease. It was found that the 
prescription of medication unique to inflammatory bowel disease 
and surgical procedures commonly utilised in the management of 
inflammatory bowel disease were highly consistent in THIN but 
with lower consistency in the oldest age groups. Some studies 
have previously demonstrated a bimodal, age-stratified distribu-
tion of incidence rates, which this study has also documented. 
However, this is not universal among inflammatory bowel disease 
epidemiological profiles, and when present, the second peak is 
often only modest.3 A higher subsequent peak in ulcerative colitis 
incidence has been previously demonstrated in a North American 
cohort 29 and more recently in a Korean study.30 This has also 
been replicated in this study and is largely driven by male sub-
jects in the older age group. Stable or slight declines in overall 
incidence have been demonstrated in a few other studies from 
the developed world.4,31,32 The finding of a reduced incidence 
rate over time in those over 50 is novel, although a study from 
Québec observed a statistically significant time-trend decline in 
annual incidence in both ulcerative colitis and Crohn's disease in 
40-49-year-olds and among ulcerative colitis subjects aged 20-29 
and 50-69 between 2001 and 2008.33 However, a bimodal peak in 
age-specific incidence was not reported and it was suggested that 
a migration effect had changed the nature of the epidemiology of 
inflammatory bowel disease in Québec.33 Migration and second 
generation changes in inflammatory bowel disease risk may also 
be playing a role in our observations. Previous studies have sug-
gested that second generation migrants to the West have a higher 
risk of inflammatory bowel disease than first generation migrants 
(either comparable or greater than the native population risk).34-
36 Disease course in inflammatory bowel disease differs with age, 
with a more aggressive disease pattern and extensive gastrointes-
tinal involvement in the young.37
The differences in the female and male incidence and prevalence 
of Crohn's disease has been demonstrated previously.38-40 A hor-
monal theory based on a reverse in incidence rates between male 
and female subjects at the time of puberty, as well as an association 
seen with hormone based medications is hypothesised.39,41
F I G U R E  4   Annual standardised 
mortality ratio for ulcerative colitis and 
Crohn's disease. CD, Crohn's disease; 
SMR, standardised mortality ratio; UC, 
ulcerative colitis
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The colorectal cancer rate in the THIN population over the study 
period was comparable to the estimated rate of 64.2 per 100 000 
persons for colorectal cancer in 2015 for the UK (age standardised: 
69.9 [95% CI 69.2-70.6]).42 This study found no decline in colorectal 
cancer rates in ulcerative colitis or Crohn's disease over the study pe-
riod, despite a significant increase in the available medications used to 
manage inflammatory bowel disease, however studies going forward 
may well find improvement. The matched cohort designs allowed for 
comparison of inflammatory bowel disease subjects with age and sex-
matched non-inflammatory bowel disease populations, while further 
adjusting for residual confounding factors. A significantly increased 
relative colorectal cancer risk in ulcerative colitis, demonstrates that 
this condition remains an important risk factor for colorectal cancer. 
However, in the incident only sensitivity analysis, there was no dif-
ference in risk between cases and controls. This most likely reflects 
a longer follow-up period in prevalent compared to incident cases 
(Appendix S5). It may also reflect that with newer diagnoses there 
is better surveillance, and more active and improved treatments, 
thereby reducing the risk of colorectal cancer in this group.
Ulcerative colitis has consistently been associated with colorec-
tal cancer when compared with the non-inflammatory bowel disease 
population, this association is not, however, consistently observed 
in Crohn's disease.8,43 It should be acknowledged that the potentially 
differing influence of Crohn's disease colitis and Crohn's disease 
small bowel disease on colorectal cancer risk were not specifically 
assessed in this study and the differing frequencies of these phe-
notypes are relevant in assessing colorectal cancer risk in Crohn's 
disease. While in this study colectomy was excluded in both ulcer-
ative colitis and Crohn's disease subjects, in Crohn's disease, par-
tial colectomy may precede the development of colorectal cancer 
and therefore some cases may be missed. More recent population 
studies and meta-analyses 7,8 have reappraised the very high historic 
colorectal cancer estimates in these conditions.6 Although beyond 
the scope of this study, there remain particular inflammatory bowel 
disease phenotypes that pose significant risks, as well as inflamma-
tory bowel disease medications that may mitigate colorectal cancer 
risk in Crohn's disease and ulcerative colitis.8
The increased risk of death observed in the current study, in 
both ulcerative colitis and in particular Crohn's disease subjects, 
has been previously demonstrated, however previous studies of all-
cause mortality in inflammatory bowel disease have been somewhat 
contradictory; Table 4 summarises the current evidence in this area. 
Although assessment of cause-specific mortality was beyond the 
scope of this present study it bears consideration. In a study from 
Olmsted County, Minnesota, looking at 1970-2016 data, the authors 
were able to look at disease-specific cause of death and found that 
gastrointestinal and respiratory causes were increased in Crohn's 
disease but not in ulcerative colitis. Ulcerative colitis was at a re-
duced risk of mortality compared to the US population, and when 
compared to matched, regional controls, the mortality risk was not 
significantly different; Crohn's disease did not differ from the back-
ground population using either methodology. This was a powerful 
study because all death certificates and ascertainment of cases were 
based on strict diagnostic criteria. However, comorbidity data were 
unavailable and it is a uniquely white and wealthy area of the country 
that may not be generalisable, not least in terms of health access and 
outcomes.44
The use of routinely gathered data from primary care has both 
limitations and strengths. Many primary care practices contribute to 
THIN, providing a representative sample of the UK population, and 
practices were required to achieve a minimum standard of quality with 
regard to data recording before participating in the study. Furthermore, 
the internal validation methodology employed has demonstrated 
that the coding of medications and surgeries commonly utilised in 
inflammatory bowel disease is frequently co-coded in those with in-
flammatory bowel disease diagnoses recorded in the THIN database. 
The inflammatory bowel diseases are generally managed by specialist 
secondary care physicians. For this reason, several medications will 
not be prescribed in primary care or coded in THIN (eg anti-TNF ther-
apy). Although this is a potential limitation, it will underestimate the 
number of subjects with coding of medications rather than implying 
a true misclassification bias in inflammatory bowel disease diagnosis 
coding. Nevertheless, miscoding as well as the lack of universal diag-
nostic definitions for inflammatory bowel disease remain a potential 
source of bias. This study has demonstrated a high prevalence of in-
flammatory bowel disease in the UK but did not use codes for indeter-
minate colitis and may therefore still underestimate the true level of 
inflammatory bowel disease in the UK. However, a significant rise in 
TA B L E  4   Studies reporting all-cause mortality risk in inflammatory bowel disease cases compared to matched controls and background 
populations
Studies reporting increased mortality risk Studies reporting decrease/equivalent mortality risk
 Crohn's Disease Ulcerative Colitis  Crohn's Disease Ulcerative Colitis
Bewtra 201351 SMR 1.40 (1.34-1.46) SMR 1.17 (1.14-1.21) Jess 200752 — SMR 1.10 (0.90-1.20)
Card 200353 HR 1.73 (1.54-1.96) HR 1.44 (1.31-1.58) Manninen 201254 SMR 1.14 (0.84-1.49) SMR 0.90 (0.77-1.06)
Duricova 201055 SMR 1.39 (1.30-1.49) — Aniwan 201844 SMR 1.25 (0.98-1.57) SMR 0.71 (0.56-0.89)
Jess 201356 HR 1.73 (1.67-1.80) HR 1.25 (1.22-1.28) Aniwan 201844 HR 1.26 (0.97-1.63) HR 0.89 (0.70-1.14)
Olén 201957 HR 1.60 (1.60-1.70) HR 1.40 (1.40-1.50)    
Canavan 200758 SMR 1.52 (1.32-1.74) —    
Abbreviations: HR, hazard ratio; SMR, standardised mortality ratio.
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prevalence across, in particular, western societies has been previously 
described.23,45 This has been attributed to falls in historic levels of mor-
tality in the inflammatory bowel diseases, improved population-wide 
longevity and high incidence. It is a potential limitation of the use of 
primary care databases that general practitioners may be improving 
their coding of prevalent disease over time. However, one would then 
expect all conditions in these databases to increase in prevalence over 
time which is not consistently the case.46-48 Moreover, better coding in 
and of itself might be expected to lead to a rise in incident cases which 
was not seen over time.
Eleven percent of ulcerative colitis cases and 13% of Crohn's 
disease cases did not have a record of an inflammatory bowel dis-
ease drug and did not have a record of an inflammatory bowel dis-
ease related surgery in the smaller, validation cohort examined. 
The distribution of ages in this group demonstrated increased 
nondrug/noncolectomy coding in older age categories. The rea-
sons for this may be multifactorial including medications only 
prescribed by secondary care: some general practitioners will not 
prescribe thiopurines due to the risks associated with these med-
ications and biologic agents are not prescribed in general prac-
tice. It has been reported that elderly patients are less commonly 
prescribed medication for their inflammatory bowel disease, and 
there may be a desire to avoid immunosuppressants by moving 
early to surgical options, following which recurrence is less com-
mon in the elderly.28,49 It is possible that a milder form of inflam-
matory bowel disease may also be represented in this group, for 
instance, a patient who has had a single flare that was managed 
with induction therapy or steroids prescribed from secondary care 
could fall into this group. Misclassification of inflammatory bowel 
disease may be a further risk, with diverticulitis and ischaemic coli-
tis potentially confusing a diagnosis in older age groups.
Although the focus of this study was on the incidence and prev-
alence of inflammatory bowel disease and the risk of mortality and 
colorectal cancer in these populations, a significant limitation is 
in identification of inflammatory bowel disease phenotype. It has 
previously been shown that disease severity, extent and comorbid 
primary sclerosing cholangitis are significant factors in the risk of 
colorectal cancer in inflammatory bowel disease.6,50 This study has 
considered all Crohn's disease and all ulcerative colitis as single dis-
eases and the paucity of data in THIN regarding inflammatory bowel 
disease phenotypic subtypes would not permit a more in-depth anal-
ysis of how these factors affect colorectal cancer and mortality risk. 
The mitigation of potential confounders was considered through 
matched cohort designs. Unfortunately, ethnicity, exercise and diet 
were often not coded and so although important factors, could not 
be included in these analyses.
Prevalence of both ulcerative colitis and Crohn's disease has been 
increasing in recent decades, while incidence appears to be declining 
to some extent, particularly in the older population. These condi-
tions remain significant risk factors for early mortality and colorectal 
cancer, particularly in ulcerative colitis. With an increasing propor-
tion of society affected, research must continue to focus on how 
best to manage these conditions and prevent adverse outcomes.
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